ZA200708110B - Solid phase bound thymosin alpha-1 and its synthesis - Google Patents

Solid phase bound thymosin alpha-1 and its synthesis

Info

Publication number
ZA200708110B
ZA200708110B ZA200708110A ZA200708110A ZA200708110B ZA 200708110 B ZA200708110 B ZA 200708110B ZA 200708110 A ZA200708110 A ZA 200708110A ZA 200708110 A ZA200708110 A ZA 200708110A ZA 200708110 B ZA200708110 B ZA 200708110B
Authority
ZA
South Africa
Prior art keywords
solid phase
synthesis
thymosin alpha
phase bound
thymosin
Prior art date
Application number
ZA200708110A
Other languages
English (en)
Inventor
Albericio Fernando
Cruz Luis Javier
Garcia Ramos Yesica
Tulla-Puche Judit
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of ZA200708110B publication Critical patent/ZA200708110B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57581Thymosin; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200708110A 2005-05-04 2007-09-20 Solid phase bound thymosin alpha-1 and its synthesis ZA200708110B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05009758 2005-05-04
US69985105P 2005-07-18 2005-07-18
PCT/EP2006/004192 WO2006117227A2 (en) 2005-05-04 2006-05-04 Solid phase bound thymosin alpha-1 and its synthesis

Publications (1)

Publication Number Publication Date
ZA200708110B true ZA200708110B (en) 2008-10-29

Family

ID=36650882

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708110A ZA200708110B (en) 2005-05-04 2007-09-20 Solid phase bound thymosin alpha-1 and its synthesis

Country Status (17)

Country Link
US (1) US20090171068A1 (de)
EP (1) EP1891104B1 (de)
JP (1) JP2008543733A (de)
KR (1) KR20080012884A (de)
CN (1) CN101166761A (de)
AT (1) ATE440856T1 (de)
AU (1) AU2006243344B2 (de)
CA (1) CA2600303A1 (de)
DE (1) DE602006008781D1 (de)
DK (1) DK1891104T3 (de)
ES (1) ES2332666T3 (de)
IL (1) IL186774A0 (de)
MX (1) MX2007013400A (de)
NO (1) NO20074623L (de)
PT (1) PT1891104E (de)
WO (1) WO2006117227A2 (de)
ZA (1) ZA200708110B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US20090149673A1 (en) * 2007-12-05 2009-06-11 Semprus Biosciences Corp. Synthetic non-fouling amino acids
CN103242443A (zh) * 2012-02-06 2013-08-14 长春百克生物科技股份公司 一种胸腺素α1及其类似物的制备方法
SG11201506885UA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of cyclic imide containing peptide products
AU2014234400B2 (en) 2013-03-21 2017-11-16 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
WO2016047794A1 (ja) * 2014-09-26 2016-03-31 株式会社カネカ 疎水性ペプチドの製造法
CN104327181A (zh) * 2014-09-28 2015-02-04 上海昂博生物技术有限公司 固相合成胸腺肽α1
CN108239147B (zh) * 2016-12-27 2023-11-10 江苏豪森药业集团有限公司 胸腺素α1衍生物的制备方法
CN111349152B (zh) * 2018-12-20 2022-04-05 深圳翰宇药业股份有限公司 一种制备胸腺法新的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341935B1 (de) * 1988-05-10 1996-04-10 Alpha-1 Biomedicals, Inc. Festphase-Verfahren zur Gewinnung von Thymosin-alpha-1
US6262230B1 (en) * 1994-01-28 2001-07-17 Sciclone Pharmaceuticals Inc. Analogs of thymosin α1
US6204360B1 (en) * 1999-12-16 2001-03-20 Usa Universe Bioengineering, Inc. Retro-inverso thymosin alpha 1 hybrids
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物

Also Published As

Publication number Publication date
AU2006243344A1 (en) 2006-11-09
WO2006117227A2 (en) 2006-11-09
DE602006008781D1 (de) 2009-10-08
JP2008543733A (ja) 2008-12-04
EP1891104B1 (de) 2009-08-26
MX2007013400A (es) 2008-04-29
CN101166761A (zh) 2008-04-23
PT1891104E (pt) 2009-12-07
IL186774A0 (en) 2008-02-09
ES2332666T3 (es) 2010-02-10
AU2006243344B2 (en) 2011-04-21
US20090171068A1 (en) 2009-07-02
ATE440856T1 (de) 2009-09-15
KR20080012884A (ko) 2008-02-12
EP1891104A2 (de) 2008-02-27
CA2600303A1 (en) 2006-11-09
WO2006117227A3 (en) 2007-03-15
DK1891104T3 (da) 2009-11-30
NO20074623L (no) 2007-12-03

Similar Documents

Publication Publication Date Title
ZA200708110B (en) Solid phase bound thymosin alpha-1 and its synthesis
GB2432609A (en) Method of expansion
HK1215932A1 (zh) 調節食慾的方法
IL192504A0 (en) Method and system for implementing ii-arq-assisted arq operation
EP1960670A4 (de) System und verfahren zum betrieb einer pumpe
GB0604346D0 (en) Method for the application of portable software
ZA200709448B (en) Modifiers for gypsum slurries and method of using them
ZA200706307B (en) Method for weighted overlap-add
GB2435062B (en) Energizing seal for expandable connections
EP1848672A4 (de) Bibliotheken und verfahren zur isolierung von antikörpern
NL2000029A1 (nl) Werkwijze voor het bedienen van een driefase-slurryreactor en een driefase-slurryreactor.
EP1896376A4 (de) Modifikatoren für gipsaufschlämmungen und verfahren zu ihrer verwendung
EP1848854A4 (de) Verfahren zur änderung der klebrigkeit von materialien
IL206072A0 (en) Novel method for generating and screening an antibody library
PL1769064T3 (pl) Instalacja biogazowa do produkcji gazów zawierających metan
GB2422678B (en) Method of making a photopolymer plate
HK1105451A1 (en) Methods for antibody library screening
IL184523A0 (en) A method of modulating t cell functioning
EP1982988A4 (de) Verfahren zur synthese von ciguatoxin ctx1b und verbindung, die für die synthese von ciguatoxin ctx1b von nutzen ist
EP2094821A4 (de) Verfahren und systeme zur beschleunigten erzeugung von methan aus einer biomasse
TW200716668A (en) Method of peptide synthesis
EP1731169A4 (de) Mittel zur behandlung von prostatahypertrophie
GB0526336D0 (en) A compiler and method for adding concurrency
GB0428507D0 (en) Blueprint for music royalties
UA29068U (ru) Способ изготовления конструкционной смеси "ПЕНОРЕЗОЛ"